| 2023/09/27 19:07:50 | |
|---|---|
| Price | |
| 834.955 USD | |
| Difference | 0.31% (2.55) |
General attributes
| ISIN | US75886F1075 |
| Symbol | REGN |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 84,068 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 834.11 USD (100) |
| Ask (Ask size) | 835.16 USD (400) |
| Open | 832.41 USD |
| High | 837.195 USD |
| Low | 831.42 USD |
| Close (prev. day) | 832.41 USD |
| VWAP | 834.836278 USD |
| Volume (pcs) | 121,726 |
| Trading volume | 101,643,940.94 |
| Number of trades | 7,528 |
| Last size | 100 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: REGENERON PHARMACEUTICALS INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/09/08 |
|
Global Equity Ratings |
|
| 2023/08/22 |
|
Global Equity Ratings |
|
| 2023/08/17 |
|
Global Equity Ratings |
|
| 2023/08/09 |
|
Global Equity Ratings |
|
| 2023/07/21 |
|
Global Equity Ratings |
|
| 2023/09/27 19:07:50 | |
|---|---|
| Price | |
| 834.955 USD | |
| Difference | 0.31% (2.55) |
General attributes
| ISIN | US75886F1075 |
| Symbol | REGN |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 84,068 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 834.11 USD (100) |
| Ask (Ask size) | 835.16 USD (400) |
| Open | 832.41 USD |
| High | 837.195 USD |
| Low | 831.42 USD |
| Close (prev. day) | 832.41 USD |
| VWAP | 834.836278 USD |
| Volume (pcs) | 121,726 |
| Trading volume | 101,643,940.94 |
| Number of trades | 7,528 |
| Last size | 100 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +1.51% | +21.32% | +45.00% |
| Perf (abs.) | +12.41 | +146.31 | +258.35 |
| Beta | 0.44 | 0.51 | 0.60 |
| Volatility | 23.71 | 26.18 | 29.18 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 829.378 USD (388,763) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 826.921 USD (453,151) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 769.972 USD (573,911) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 760.632 USD (612,178) |
| YTD High | date | 847.500 USD (2023/08/22) |
| YTD Low | date | 668.000 USD (2023/01/09) |
| 52 Weeks High | date | 847.500 USD (2023/08/22) |
| 52 Weeks Low | date | 668.000 USD (2023/01/09) |
All listings for REGENERON PHARMACEUTICALS INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2023/09/27 | 17:35 | 795.00 EUR | 0.20 | 4 |
| Vienna Stock Exchange | 2023/09/27 | 17:32 | 794.50 EUR | 0.00 | 2 |
| Tradegate | 2023/09/27 | 18:47 | 794.00 EUR | 0.27 | 10 |
| Stuttgart | 2023/09/27 | 11:08 | 787.00 EUR | 0.00 | 4 |
| Nasdaq | 2023/09/27 | 19:07 | 834.955 USD | 101.64 | 7,528 |
| Munich | 2023/09/27 | 08:02 | 786.50 EUR | 0.00 | 1 |
| London Stock Exchange | 2023/09/06 | 17:18 | 825.24 USD | 0.05 | 1 |
| Hanover | 2023/09/27 | 08:16 | 788.00 EUR | 0.00 | 1 |
| Hamburg | 2023/09/27 | 08:06 | 788.00 EUR | 0.00 | 1 |
| Frankfurt | 2023/09/27 | 15:43 | 793.50 EUR | 0.00 | 3 |
| Duesseldorf | 2023/09/27 | 16:30 | 793.00 EUR | 0.00 | 4 |
| Berlin | 2023/09/27 | 08:02 | 786.50 EUR | 0.00 | 1 |
| BX Swiss | 2023/09/25 | 18:00 | 755.339 CHF | 0.02 | 1 |
Company Logo
Contact Details
| REGENERON PHARMACEUTICALS INC. |
| - - |
| 777 Old Saw Mill River Road - 10591-6707 Tarrytown |
| Telefon: +1-914-847-7000 |
| Fax: + |
| E-mail: - |
PDF Downloads
| Company report: REGENERON PHARMACEUTICALS INC. | |
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY. |
Members of Management Board
| George Yancopoulos | Chairman of Board of Directors |
| Bonnie Bassler | Member of Board of Directors |
| Craig Thompson | Member of Board of Directors |
| David Schenkein | Member of Board of Directors |
| Huda Zoghbi | Member of Board of Directors |
| Joseph Goldstein | Member of Board of Directors |
| Kathryn Guarini | Member of Board of Directors |
| Michael Brown | Member of Board of Directors |
| N. Coles | Member of Board of Directors |
| Arthur Ryan | Member of Board of Directors |
| Christine Poon | Member of Board of Directors |
| George Sing | Member of Board of Directors |
| Leonard S. Schleifer | Chairman of Managing Board |
| George D. Yancopoulos | Member of Executive Committee |
| Robert E. Landry | Member of Executive Committee |